Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Comment: Improved 2 year survival for pancreatic cancer with pre-operative chemoradiation

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 536

Dr Andrew Epstein, Prof Richard Schilsky and Dr Geertjan van Tienhoven

Dr Andrew Epstein, Prof Richard Schilsky and Dr Geertjan van Tienhoven comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from the PREOPANC-1 trial.

This was a phase III randomised trial in which patients with resectable pancreatic cancer received 10 weeks of chemoradiotherapy prior to surgery, or immediate surgery alone.

For more on these results, watch Dr van Tienhoven present this data in a press conference here, watch Dr van Tienhovens interview with ecancer here, or read news coverage here.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation